NATCO launches Albupax to treat breast cancer

Hyderabad, Sep 19 (UNI) City-based NATCO Pharma Limited today launched its first nano technology drug 'Albupax', the first generic version of international brand Abraxane, for treatment of breast cancer.

Albupax, which consists of Paclitaxel in an Albumin-bound nano particle form, replaces the conventional Paclitaxel and has the advantage of having least side effects, a press release here said.

Indigeneously developed by NATCO in India, the drug claimed to be the first albumin-bound Paclitaxel in nano-particle to be developed in India. Each 100 mg vial of Albupax is priced at Rs 11,500, the release added.